RESUMEN
Background: Treatment inertia, non-adherence and non-persistence to medical treatment contribute to poor blood pressure (BP) control worldwide. Fixed dose combination (FDC) antihypertensive medicines simplify prescribing patterns and improve adherence. The aim of this study was to identify factors associated with prescribing FDC antihypertensive medicines and to understand if these factors differ among doctors worldwide. Methods: A cross-sectional survey was conducted online from June 2023 to January 2024 to recruit doctors. We collaborated with an international network of researchers and clinicians identified through institutional connections. A passive snowballing recruitment strategy was employed, where network members forwarded the survey link to their clinical colleagues. The survey instrument, developed through a literature review, interviews with academic and clinical researchers, and pilot testing, assessed participants perspectives on prescribing FDC antihypertensive medicines for hypertension. Participants rated their level of agreement (5-point Likert scale) with statements representing six barriers and four facilitators to FDC use. Findings: Data from 191 surveys were available for analysis. 25% (n = 47) of participants worked in high-income countries, 38% (n = 73) in upper-middle income, 25% (n = 48) in lower-middle income, 6% (n = 10) in low-income countries. Forty percent (n = 70) of participants were between 36-45 years of age; two thirds were male. Cost was reported as a barrier to prescribing FDC antihypertensive medicines [51% (n = 87) agreeing or strongly agreeing], followed by doctors' confidence in BP measured in clinic [40%, (n = 70)], access [37%, (n = 67)], appointment duration [35%, (n = 61)], concerns about side-effects [(21%, n = 37)], and non-adherence [12%, (n = 21)]. Facilitators to FDC antihypertensive polypills prescribing were clinician facing, such as access to educational supports [79%, (n = 143)], more BP measurement data [67%, (n = 120)], a clinical nudge in health records [61%, (n = 109)] and patient-facing including improved patient health literacy [49%, (n = 88)]. The levels of agreement and strong agreement across all barriers and facilitators were similar for participants working in higher or lower income countries. Across all countries, participants rated FDC antihypertensive medications highly valuable for managing patients with non-adherence, (82% reported high or very high value), for patients with high pill burden (80%). Interpretation: Cost and access were the most common barriers to prescribing FDCs across high- and low-income countries. While greater educational support for clinicians was perceived as the leading potential facilitator of FDC use, this seems unlikely to be effective without addressing access.
Asunto(s)
Antihipertensivos , Hipertensión , Pautas de la Práctica en Medicina , Humanos , Antihipertensivos/uso terapéutico , Antihipertensivos/administración & dosificación , Estudios Transversales , Hipertensión/tratamiento farmacológico , Masculino , Femenino , Pautas de la Práctica en Medicina/estadística & datos numéricos , Adulto , Persona de Mediana Edad , Prescripciones de Medicamentos/estadística & datos numéricos , Encuestas y Cuestionarios , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Cumplimiento de la Medicación/estadística & datos numéricos , Combinación de MedicamentosRESUMEN
BACKGROUND: Left atrial remodelling (LAR) has been described in Western populations with chronic hypertension and is associated with a higher risk of adverse cardiovascular events. Although hypertension tends to occur earlier and is more severe in sub-Saharan Africa than in more developed nations, LAR and its associated factors in these African hypertensive subjects have been poorly elucidated. OBJECTIVES: To assess left atrial structural remodelling in black hypertensive patients and determine factors associated with left atrial size. METHODS: This was a cross-sectional, comparative study carried out in two tertiary hospitals in Douala, Cameroon over a period of three months. Fifty-two patients, either newly diagnosed with hypertension or known hypertensives treated for less than a year, were consecutively recruited. These patients were matched (unpaired matching) for age and gender to 40 randomly selected healthy subjects. The posterior-anterior diameter indexed to body surface area (BSA), volume indexed to BSA, and longitudinal and transverse diameters of the left atrium (LA) were measured using transthoracic echocardiography, in accordance with the American Society of Echocardiography guidelines. LAR was defined as increase in LA size, characterised by LA volume ≥ 34 ml/m2. Early morning urine was analysed for microalbuminuria using urine strips to obtain spot albumin/creatinine ratio. Data were analysed using SPSS version 23 and statistical significance was set at p < 0.05. RESULTS: The gender distribution and mean age were similar between the two groups. Hypertensive patients had significantly higher mean body mass index, left ventricular mass and an altered diastolic function. They also had significantly higher LA longitudinal diameter (50.0 vs 47.4 mm; p = 0.045), surface area (17.9 vs 15.5 cm2; p = 0.003) and volume (52.4 vs 43.8 ml; p = 0.002) compared to the non-hypertensive counterparts. Fourteen patients (26.9%) had LA enlargement compared to one (2.5%) in the non-hypertensive group (odds ratio = 9.78, CI: 2.67-35.8, p < 0.0001). Diastolic dysfunction (p = 0.008) was the only independent predictor of LA size in the hypertensive subjects. Microalbuminuria did not significantly correlate with LA size. CONCLUSIONS: Our study shows evidence of LAR in newly diagnosed black African patients with hypertension, characterised by an increase in the LA length, surface area and volume. Future studies are warranted to better elucidate the biological mechanisms underlying the link between the early phase of hypertension and LAR, as well as its prognostic implications in our population.